Targeted Oncology
Targeted Oncology
Targeted Oncology

Specialties

A Study Investigating Pembrolizumab in Combination With Eribulin in TNBC

Sara Tolaney, MD, MPH
Published Online:10:42 AM, Tue January 3, 2017

Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer. 
Publications